AERI Aerie Pharmaceuticals, Inc.

42.20
+0  (0%)
Previous Close 42.10
Open 42.25
Price To book 13.37
Market Cap 1.42B
Shares 33,626,000
Volume 206,600
Short Ratio 7.09
Av. Daily Volume 375,997

SEC filingsSee all SEC filings

  1. 8-K - Current report 17765970
  2. 8-K/A (Amend) - Current report 17759173
  3. 8-K - Current report 17758033
  4. 8-K - Current report 17736172
  5. S-8 - Securities to be offered to employees in employee benefit plans 17679207

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 Mercury 1 data released September 14, 2016. Primary endpoint met. Mercury 2 trial data due 2Q 2017.
Roclatan - Mercury trials
Glaucoma
NDA Filing September 6, 2016 withdrawn due to third party manufacturing issues. NDA resubmission announced March 1, 2017.
Rhopressa
Glaucoma

Latest News

  1. Implied Volatility Surging for Aerie Pharmaceuticals (AERI) Stock Options
  2. Aerie Reports Positive Data on Ophthalmic Drug Rhopressa
  3. After-hours buzz: PIR, HBI & AERI
  4. Aerie Pharmaceuticals Reports Positive Rocket 4 Six-Month Topline Safety and Efficacy Results for RhopressaTM (netarsudil ophthalmic solution) 0.02%
  5. 3 Clinical-Stage Biotech Stocks That Could Be About to Strike It Rich
  6. Aerie Pharmaceuticals Announces Expansion of Commercialization Team
  7. Aerie (AERI) Down 12.9% Since Earnings Report: Can It Rebound?
  8. Blog Coverage AstraZeneca's Lung Cancer Drug Received Full Approval from FDA
  9. Aerie Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
  10. Blog Coverage Novartis Licences its Immunosenescence Drugs to PureTech Health
  11. Aerie Resubmits Rhopressa NDA, Roclatan Gains Traction
  12. Aerie (AERI) Q4 Loss Widens, Rhopressa NDA Resubmitted
  13. Aerie reports 4Q loss
  14. Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
  15. 4 Small-Cap Biotech Stars
  16. Aerie Pharmaceuticals to Present at Three Investor Conferences in March
  17. Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?
  18. Aerie Pharmaceuticals Announces Resubmission of NDA for RhopressaTM (netarsudil ophthalmic solution) 0.02%
  19. Aerie Pharmaceuticals to Announce Fourth Quarter and Year End 2016 Financial Results and Host Conference Call on Tuesday, March 7, 2017
  20. Aerie Pharmaceuticals to Present at the RBC Capital Markets 2017 Global Healthcare Conference

SEC Filings

  1. 8-K - Current report 17765970
  2. 8-K/A (Amend) - Current report 17759173
  3. 8-K - Current report 17758033
  4. 8-K - Current report 17736172
  5. S-8 - Securities to be offered to employees in employee benefit plans 17679207
  6. S-8 - Securities to be offered to employees in employee benefit plans 17679125
  7. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17678944
  8. 8-K - Current report 17672002
  9. 8-K - Current report 17669570
  10. 8-K - Current report 17651349